Cardiolipin alleviates insulin resistance by ameliorating mitochondrial dysfunction and promoting fatty acid oxidation
Journal of Molecular Endocrinology · 01.04.2026 · 76 (3)
DOI: 10.1530/jme-25-0103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Endocrinology, online erschienen am 25.03.2026. Verfasst von Chengcheng Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, PR China. Hauptthemen laut MEDLINE: Insulin Resistance, Cardiolipins, Fatty Acids, Mitochondria. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Youth Beijing Scholar, Key Discipline of the National Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
Cardiolipin deficiency is closely associated with mitochondrial dysfunction and metabolic disorders, yet whether it directly modulates insulin resistance remains unknown. Here, we examined the effects of cardiolipin supplementation on insulin resistance and the underlying mechanisms using male C57BL/6J mice fed a high-fat diet, male db/db mice, and dexamethasone-induced insulin-resistant HepG2 cells, a well-established model for investigating hepatic insulin signaling. Intragastric administration of cardiolipin at 5 mg/kg lowered blood glucose, reduced weight gain, improved insulin sensitivity, and alleviated hepatic lipid accumulation in mice, along with decreased serum interleukin-6 and low-density lipoprotein cholesterol levels. Cardiolipin reduced the LC3-II/LC3-I ratio and Tom20 expression in both liver tissue and insulin-resistant HepG2 cells, indicative of enhanced mitophagy. In HepG2 cells, it also attenuated mitochondrial fragmentation, improved mitochondrial membrane potential, lowered reactive oxygen species production, and upregulated the expression of CPT1A and ACAD1. These findings demonstrate that cardiolipin mitigates hepatic insulin resistance by enhancing mitophagy and fatty acid oxidation, representing a promising therapeutic approach for insulin resistance-related metabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, PR China.
- Beijing Key Laboratory of Clinical-Based Innovative Drug R&D of Traditional Chinese Medicine, Beijing, PR China.
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, PR China.
ORCID-Profile: Dan Yan
Förderung
- National Natural Science Foundation of China
- Youth Beijing Scholar
- Key Discipline of the National Administration of Traditional Chinese Medicine
- Beijing Medical and Health Collaborative Traditional Chinese Medicine High-quality R&D Project
Zitieren
APA
Yao, C., Long, J., Wang, Y., Liu, X., Qiu, T., Chen, K., & Yan, D. (2026). Cardiolipin alleviates insulin resistance by ameliorating mitochondrial dysfunction and promoting fatty acid oxidation. Journal of Molecular Endocrinology, 76(3). https://doi.org/10.1530/jme-25-0103
Vancouver
Yao C, Long J, Wang Y, Liu X, Qiu T, Chen K, et al. Cardiolipin alleviates insulin resistance by ameliorating mitochondrial dysfunction and promoting fatty acid oxidation. Journal of Molecular Endocrinology. 2026;76(3). doi:10.1530/jme-25-0103
BibTeX
@article{Yao2026,
author = {Yao, Chengcheng and Long, Jianglan and Wang, Yueyue and Liu, Xiaojia and Qiu, Tingting and Chen, Kuan and Yan, Dan},
title = {Cardiolipin alleviates insulin resistance by ameliorating mitochondrial dysfunction and promoting fatty acid oxidation},
journal = {Journal of Molecular Endocrinology},
year = {2026},
volume = {76},
number = {3},
doi = {10.1530/jme-25-0103}
}
EUVIMED